NTT-DATA
NTT DATA, a global digital business and IT services leader, today announced a new global banking research report entitled "The Digital Horizon: Banking’s Shift from Mainframe to AI-Driven Cloud Infrastructure.” The research has unveiled findings from a survey of 650 global banking decision-makers, marking a definitive shift in the sector towards agile and customer-focused banking. Moreover, the survey uncovers a transformative trend: banks are finally pivoting from entrenched mainframe systems to adopt AI and cloud technologies, spurred by the multiple headwinds they face of consumer demands, innovative new market disruption, and the competitive pressures of innovative technological advancements.
Modernisation and Transformation Trends:
- Enduring Mainframes: Despite 89% of banking leaders identifying as innovators, 63% still operate on mainframe systems, confirming the mainframe’s resilience.
- Cloud Migration to Increase from Generative AI injection: 63% of banking decision-makers confirm generative AI is decisively facilitating the transition of banking applications to the cloud
- Generative AI Gaining Board-Level Support: A resounding 91% report their AI and cloud initiatives are endorsed by the board, signalling strategic prioritisation.
- Navigating Skill Gaps: With 80% lacking a strategic framework for generative AI adoption, the need for upskilling is evident.
- 45% of banks are already integrating generative AI technology into their technology stacks while a further 30% are in the early stages of looking at it.
- Cloud as an Innovation Enabler: Flexibility and scalability are cited by 36% of respondents as key drivers for cloud migration, indicating a shift beyond cost concerns.
The enduring stronghold of mainframes in the banking sector is poised for a significant shift, thanks to the integration of generative AI into cloud migration strategies. NTT DATA's research reveals that 63% of banking decision-makers confirm generative AI is decisively facilitating the transition of banking applications to the cloud, indicating a transformative phase where mainframes’ resilience meets the agility of cloud computing.
25% of respondents also acknowledge a growing trend in cloud migration, propelled by AI advancements. This heralds a new era where the collaboration between AI’s potential to reinterpret legacy code and cloud technology's scalability is accelerating modernisation and transformation initiatives, suggesting that the longstanding reign of mainframes is approaching its horizon.
Kaz Nishihata, Director and Senior Executive Vice President at NTT DATA Group Corporation, commented: "Banks are not only evolving technologically but also culturally. The industry’s rapid adoption of AI and cloud is redefining business models and establishing a new norm in sector leadership. This technological tide is propelling banks toward a more intimate understanding of customer needs, delivering services that are faster, more secure, and uniquely tailored."
The research also found that the banking industry is rapidly embracing the transformative power of generative AI, with 45% of banks already incorporating it into their operations. Additionally, 30% are exploring its potential, signalling a proactive shift towards innovation. This adoption underscores the sector's commitment to future-proofing services and the desire for organisations to enhance their competitive edge in a fast-evolving digital landscape.
Nishihata adds, “The momentum for generative AI across the banking sector is a testament to the industry’s resolve to move beyond traditional mainframes, leveraging cloud environments to fortify security, enhance robustness, innovate, and boldly redefine. This transition promises a new era of innovation.”
To read the full report, visit "The Digital Horizon: Banking’s Shift from Mainframe to AI-Driven Cloud Infrastructure"
About the research
NTT DATA's survey canvasses a diverse array of banking professionals, from all global banking markets, and provides a 360-degree perspective on the sector's modernisation and journey towards innovation and transformation.
Demographics of Respondents:
- Global Insights: Leaders from a broad geographic spectrum, including the United States, the United Kingdom, Japan, Germany, Spain, Italy, Mexico, and Brazil.
- Institutional Scope: A cross-section from multinational banks to local banking institutions.
- Expertise Range: Perspectives across IT, Operations, Innovation, and Strategy.
About NTT DATA
NTT DATA – a part of NTT Group – is a trusted global innovator of IT and business services headquartered in Tokyo. We help clients transform through consulting, industry solutions, business process services, IT modernisation and managed services. NTT DATA enables clients, as well as society, to move confidently into the digital future. We are committed to our clients’ long-term success and combine global reach with local client attention to serve them in over 50 countries. Visit us at nttdata.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208750914/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom